Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Microchip Technology Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Microchip Technology Inc. trades at $88.16 (market cap $47.30B). The key difference: Microchip Technology Inc. is far larger — about 5.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Microchip Technology Inc. pays a 2.09% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MCHP | |
|---|---|---|
Market Cap | $8.04B | $47.30B |
Sector | Health | Technology |
52-Week High | $339.75 | $102.97 |
52-Week Low | $241.71 | $49.02 |
Enterprise Value | $7.85B | $52.60B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Microchip Technology (MCHP) trades at $84.23, down 4.92% in the last session, with a bearish technical signal and support near $81. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, while revenue declined to $4.40B. Analyst consensus remains strongly bullish with a $113.33 price target, supported by positive news on AI and aerospace demand.
MCHP faces near-term pressure from weak profitability and high debt, but long-term growth is supported by AI, data center, and aerospace exposure. Risks include cyclical semiconductor demand and execution challenges, yet institutional sentiment and recent product launches suggest potential recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
